RESUMO

Antitumour activity of cytotoxic agents, evaluated in patients with AIDS-related Kaposi's sarcoma (KS), is about 30-80%. However, responses are mostly partial and short. Experience with etoposide is similar. Teniposide has a longer elimination half-life and superior antitumour activity compared with etoposide in some experimental models. Thus a phase II trial was done in 25 patients with AIDS-related KS. Teniposide was given by 60-min infusion at 360 mg/m2 every 3 weeks. 10 (40%) showed a partial response, median duration of 9 (6-20) weeks. The main side-effects were leukopenia, thrombocytopenia, nausea and vomiting, alopecia and mucositis.

Assuntos

Síndrome da Imunodeficiência Adquirida/complicações , Sarcoma de Kaposi/tratamento farmacológico , Teniposídeo/uso terapêutico , Adulto , Alopecia/induzido quimicamente , Avaliação de Medicamentos , Humanos , Leucopenia/induzido quimicamente , Masculino , Náusea/induzido quimicamente , Sarcoma de Kaposi/etiologia , Teniposídeo/efeitos adversos , Trombocitopenia/induzido quimicamente , Fatores de Tempo